Ameriprise Financial Inc Supernus Pharmaceuticals, Inc. Transaction History

Ameriprise Financial Inc

$358 Billion
Q1 2024

A detailed history of Ameriprise Financial Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 566,270 shares of SUPN stock, worth $15.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

566,270

Previous 559,702 1.17%

Holding current value

$15.4 Million

Previous $16.2 Million 19.25%

% of portfolio

0.01%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$27.11 - $35.17 $178,058 - $230,996	6,568 Added 1.17%	566,270 $19.3 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $211,682 - $276,528	-9,317 Reduced 1.64%	559,702 $16.2 Million
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $722,499 - $862,439	-26,206 Reduced 4.4%	569,019 $15.7 Million
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $2.5 Million - $3.24 Million	-83,614 Reduced 12.32%	595,225 $17.9 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $679,423 - $817,525	-19,451 Reduced 2.79%	678,839 $24.6 Million

Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $2.96 Million - $3.61 Million	-95,267 Reduced 12.01%	698,290 $24.9 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $906,971 - $1.12 Million	-31,503 Reduced 3.82%	793,557 $26.9 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $563,719 - $762,233	-22,255 Reduced 2.63%	825,060 $23.9 Million
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $626,849 - $723,372	21,987 Added 2.66%	847,315 $27.4 Million
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $374,190 - $485,581	-14,190 Reduced 1.69%	825,328 $24.1 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $853,960 - $1.14 Million	36,277 Added 4.52%	839,518 $22.4 Million
Q2 2021 Aug 16, 2021	BUY	$26.72 - $33.19 $1.02 Million - $1.27 Million	38,264 Added 5.0%	803,241 $24.7 Million
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $239,640 - $312,078	9,923 Added 1.31%	764,977 $20 Million
Q4 2020 Feb 12, 2021	BUY	$17.7 - $25.81 $1.14 Million - $1.66 Million	64,316 Added 9.31%	755,054 $19 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $1.06 Million - $1.31 Million	52,493 Added 8.22%	690,738 $14.4 Million
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $2.48 Million - $3.61 Million	-145,047 Reduced 18.52%	638,245 $15.2 Million
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $336,439 - $574,857	23,283 Added 3.06%	783,292 $14.1 Million
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $2.58 Million - $3.77 Million	129,434 Added 20.53%	760,009 $18 Million
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $1.56 Million - $2.05 Million	-61,383 Reduced 8.87%	630,575 $17.3 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $7.45 Million - $9.66 Million	248,525 Added 56.05%	691,958 $22.9 Million
Q1 2019 May 15, 2019	SELL	$32.77 - $41.99 $1.19 Million - $1.53 Million	-36,404 Reduced 7.59%	443,433 $15.5 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $661,918 - $1.06 Million	21,463 Added 4.68%	479,837 $15.9 Million
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $3.88 Million - $5.14 Million	-90,891 Reduced 16.55%	458,374 $23.1 Million
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $1.77 Million - $2.4 Million	-40,170 Reduced 6.82%	549,265 $32.9 Million
Q1 2018 May 15, 2018	SELL	$37.15 - $46.9 $413,070 - $521,481	-11,119 Reduced 1.85%	589,435 $27 Million
Q4 2017 Feb 12, 2018	SELL	$36.4 - $42.6 $2.96 Million - $3.46 Million	-81,238 Reduced 11.92%	600,554 $23.9 Million
Q3 2017 Nov 07, 2017	BUY	$36.75 - $49.65 $25.1 Million - $33.9 Million	681,792	681,792 $27.3 Million

Others Institutions Holding SUPN

# of Institutions

260

Shares Held

57.3M

Call Options Held

84.1K

Put Options Held

61.2K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.45B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Supernus Pharmaceuticals, Inc. Transaction History